Targeted delivery of modified RNAs to the liver – an alternative Hepatitis C therapeutics


Nowadays more than 150 million people in the world suffer from hepatitis C virus (HCV) and more than 2 billion people are infected by hepatitis B virus (HBV). These infections affect the liver and lead to cirrhosis and liver cancer. Today at least 3 mln people in Russia are infected by HCV, the average lifetime cost of the disease is estimated at 3 mln RUR. Recently Regulus Therapeutics presented new data for clinical trials (stage II) of RG-101 inhibitor. RG-101 treatments lead viral load reductions of 4-5log were achieved following a single subcutaneous administration of 4mg/kg, making RG-101 the single most potent HCV drug ever tested. RG-101 is a conjugate of modified RNA with N-acetylgalactosamine.